dopamine D3 receptor antagonist F17464

10/01/2019 - "This 6-week trial demonstrated therapeutic efficacy of 40 mg/day F17464 in improving symptoms of acute exacerbation of schizophrenia with a favorable safety profile."
10/01/2019 - "This phase II, double-blind, randomized, placebo-controlled, parallel-group study in five European countries evaluated the efficacy and safety of F17464, 20 mg twice daily, versus placebo over 6 weeks in patients with acute exacerbation of schizophrenia. "
10/01/2019 - "Randomized, double-blind, placebo-controlled study of F17464, a preferential D3 antagonist, in the treatment of acute exacerbation of schizophrenia."
01/01/2017 - "Two D3 receptor-selective compounds have reached clinical trials in schizophrenia, with negative results seemingly due to insufficient target engagement; the results with a third compound, F17464, have not been disclosed yet. "
10/01/2019 - "F17464, a highly potent preferential D3 antagonist, is a novel compound in development for schizophrenia treatment. "

10/01/2019 - "Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. "

10/01/2019 - "Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. "

10/01/2019 - "The most common AEs in F17464 group: insomnia, agitation, and increased triglycerides; worsening of schizophrenia/drug ineffective was less frequent in F17464. "

10/01/2019 - "Interestingly, no weight gain, no extrapyramidal disorder except rare akathisia were observed under F17464. "